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I. Methods 
A. Prediction of the Initial Helical Bundle  
Specifically, we used the PredicTM method to compare with DP the sequences of ~1000 GPCRs 
having sequence identities down to 5%, aligning them to the DP sequence using the Multiple Alignment using 
Fast Fourier Transform (MAFFT) method. We then used the Wimley-White hydrophobicity scale9 to evaluate 
the average hydrophobicity along the target sequence for all 1000 GPCRs. We used this to predict the TMD 
that lies in the membrane (with positive hydrophobicity). These “raw” helix predictions are then “capped” by 
extending by 1 to 5 residues on both N and C-termini until a helix breaker residue (charged residues, prolines, 
and glycines) is found. The final hydrophobicity profile (Figure S2) was used to predict which part of the DP 
sequence corresponds to each transmembrane helix (Figure S1) and the HPC at z=0 to align all 7 helices to a 
common x-y plane.   
II. Structural Comparisons 
A. Comparison of DP-Li/T, DP-Li/Topt, DRD3/T low-energy structures from SuperbiHelix 
In analyzing the top-ranked structures from all 3 templates (DP-Li/T, DP-Li/Topt, DRD3/T) after 
SuperBiHelix (Table 1), we find that the main interactions from the DuplexBiHelix level are maintained in all 
3 templates. In particular, we note that all three templates maintain the salt-bridges from the DuplexBiHelix 
level (D722.50 - K762.54, R2846.54 – E3047.34, K2916.61 – D2926.62). In all 3 template derived structures, we see the 
formation of an additional favorable salt-bridge (< -30 kcal/mol) on TM7 between E3047.34 - R3077.37, where 
both charged residues are unique to DP in the prostaglandin family. For all templates, we also generally see the 
maintenance of the same 1-2-7 interhelical interactions (N341.50 – D722.50 - K762.54 – S3167.46). Below we note 
the differences between the top-ranked structures for each template: 
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One of the main differences between the top-ranked structures from all 3 templates is the interaction of 
D3197.49. The experimental analysis by Audoly and Breyer8 finds that this aspartic acid (D3197.49) on TM7 does 
not participate directly in the receptor-ligand binding. Rather, it may provide the receptor flexibility to undergo 
conformational changes during activation. This is consistent with previous antagonist and agonist studies on 
DP., which find the aspartic acid interacts with TM3 and does not participate directly in binding. In DP-Li/T 
top-ranked structures, we find that Q1223.42 forms a hydrogen bond D3197.49, which is of significance since 
Q1223.42 is unique to the DP receptor, and it has been implicated in stabilizing the inactive conformation in our 
previous dynamical studies on DP1. In DRD3/T top-ranked structures, we find the formation of a strong 
alternate 2-7 interaction between D3197.49 and K762.54 (~-35 kcal/mol), where Asp is fully conserved in the 
prostaglandin family. This interaction is only found in the DRD3/T structures, due to the tighter binding pocket 
(Figure S3), which we have discussed extensively below. In the DP-Li/Topt based structures, we find that the 
aspartic acid on TM7 has no interaction with either TM2 or TM3 (like in the other cases). Due to the large 
rotation of TM3 in the DP-Li/Topt case, Q1223.42, which interacts with the Asp on TM7 in DP-Li/T case, forms 
an alternate interaction with S1604.50 on TM4. In comparing the interactions of D3197.49 in all 3 cases, we 
expect DP-Li/T based structures to be more favorable, since the Asp has an interaction partner (proton 
acceptor) in this case and likely will not interfere with the binding of the ligand in the extracellular end of the 
binding pocket.  
Another interaction of interest is that uniquely in DP-Li/Topt cases, we find the strong salt-bridge 
interaction between E1293.49– R2235.55 is maintained through SuperBiHelix. This glutamic acid is of particular 
interest, since DP lacks the “E/DRY” motif at the intra-cellular end of TM3, which is found in 97%2 of Class 
A-GPCRs and has been implicated in activation for receptors such as rhodopsin. This likely indicates that the 
glutamic acid on TM3 has an alternate functionality in DP activation as compared to other Class A and 
prostaglandin GPCRs. In the DRD3/T case, we find that the large rotation of TM5 (SI Table 2) allows R2235.55 
to form a strong alternate interaction with T1203.40 (~-11 kcal/mol). In DP-Li/T case, the R2235.55 forms a weak 
hydrogen bond interaction with T2716.41, while in some top-ranked DP-Li/T receptors E1293.49   forms a salt-
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bridge interaction with the fully conserved R2305.62. Since there is limited experimental data on the effect of the 
alternate ECW motif in DP, it is hard to definitively determine which of these interactions are more likely to be 
found in the inactive structure. However, given our previous dynamics studies1 in DP, which found that TM3 
rotation was characteristic of agonist binding, we predict that the interaction of E1293.49 is one of the features in 
DP that stabilizes the receptor in the inactive conformation.   To further investigate the role of the lack of 
“DRY” motif in DP binding and activity, we urge mutation studies on E1293.49. 
B. Comparison of DP-Li/T, DP-Li/Topt, DRD3/T docked structures 
We did not select the DRD3/T and DP-Li/Topt structures for further relaxation in dynamics. We will 
first discuss the DRD3/T docked structures. Experimental studies of chimeric mouse data for prostaglandin 
compounds3,6,7 suggest that the ligand-binding pocket for prostaglandin receptors is mainly comprised of the 
first, second, and seventh TM domains.  However, the SuperCombiHelix structures using the DRD3/T 
template, lead to antagonist binding sites in the upper-half of the pocket of TM1-2-3-7 regions. Using the 
DRD3 template leads to a tighter 1-2-7 upper region binding pocket compared to the same region for the 
SuperCombiHelix structures from the other two templates (DP-Li/T, DP-Li/Topt) to which we docked the 
antagonist. Specifically, we find in the binding pocket (shown in Figure S2), the antagonist has particularly 
poor interactions with V83, with the vdW energy greater than 15.0 kcal/mol, even after running SCREAM10 
and minimization on the binding site as part of our docking procedure.  
Additionally, in comparing DRD3/T and DP-Li/T, we note that the antagonist tends to bind 
horizontally to SuperCombiHelix structures based on the DRD3/T template, whereas structures based on DP-
Li/T prefer a vertical binding site. We found complexes with strong interactions with Arg7.40 and Lys2.54 were 
most energetically favorable. For the receptor based on the DRD3/T template, (Figure S3) the antagonist binds 
horizontally in the TM1-2-7 binding pocket, which still captures the strong salt bridge of the antagonist 
carboxylate with the fully-conserved R3107.40 in the prostaglandin receptor family3 on TM7. However, the 
horizontal orientation captures fewer interactions between the sulfonyl group and the neighboring receptor 
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residues. In contrast, the binding site based on the DP-Li/T finds leads to attractive interactions of the sulfonyl 
group with K762.54, which is not seen in the DRD3/T based binding sites.  
It is well-known that the DP receptor shows strict preferential binding to the PGD2 endogenous 
ligand3,7. Kobayashi et. al7 suggested for that for hDP, K762.54 helps confer the selectivity of DP for the 
corresponding endogenous ligand.  However, the tight binding pocket for the DRD3/T SuperBiHelix structures 
makes it difficult for the antagonist to bind vertically in the TM1-2-7 region to form the contact with K762.54 
that is implicated in the functional behavior of DP. 
Regarding the DP-Li/Topt cases, similar to DP-Li/T and DRD3/T, we find that the ligand-binding 
pocket is mainly comprised of the TM1, TM2, and TM7 domains. In comparing DP-Li/T and DP-Li/Topt, we 
find that DP-Li/T tends to have favorable receptor-ligand complexes due to a strong interaction between the 
carboxylic acid on the antagonist and R3107.40 on TM7. Instead in DP-Li/Topt based structures, we find that the 
bulky leucine residue L3097.39 tends to occupy the binding pocket, which severely restricts the ability of the 
antagonist to comfortably bind in the extracellular region (Figure S4). We also note that the helices built 
through DP-Li/Topt55 have less flexibility, since OptHelix leads to perfect starting helices, before introducing 
kinks due to proline and glycine. In contrast, the DP-Li/T structure1 has more helical flexibility that allows 
more room for the ligand to bind in the upper-half of the binding pocket region, while maintaining favorable 
interactions in the bottom half of the TM1-2-7 trans-membrane region such as S1193.39-D3197.49. Due to the 
critical role of TM7 in DP function and ligand binding1,5,7, we anticipate that TM7 flexibility plays a role in DP 
activation. In particular, we found in our previous MD studies on DP1, that agonist binding caused the breaking 
of a 2-7 interaction, which resulted in a rotation of TM3 and TM7. Consequently, we predict that the 
interactions found within the bottom half of the TM region are important characteristics of the DP inactive 
structure. Therefore, we inserted the selected DP-Li/T complex into a periodic box with a lipid bilayer and 
filled with water, which we equilibrated for 100 nanoseconds.  
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Figure S1. Sequence alignment of PD2R receptor against the other prostaglandin receptors: PE2R1, PE2R2, PE2R3, 
PE2R4, PI2R, TA2R, and PF2R.  The conserved residues are boxed and the X.50 residue (Ballesteros numbering (11)) 
has been marked in yellow. Also, the D/ERY motif, implicated in activation of many class A GPCRs has been marked. 
Unlike for most other prostaglandin GPCRs, the DP receptor does not have an arginine in the conserved “DRY” motif. 
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Figure S2.  The seven transmembrane (TM) regions of DP1 based on average hydrophobicity from the multiple 
sequence alignment using PredicTM. 
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Table S1 & S2: ComBiHelix Results for DP Receptor based on: (a) previous computational MD DP structure (DP-Li/T), 
(b) GEnSeMBLE OptHelix DP helices (based on the previous computational DP template) (DP-Li/Topt), (c) DP 
Receptor with Dopamine (DRD3) Homology Template η Values following 1-2-7 sampling and 3-4-5-6 sampling 
(DRD3/T). 
receptor variants at the BiHelix level for 
TMD 1-2-7 top n H1 H2 H3 H4 H5 H6 H7 CInterH CTotal NInterH NTotal
Previous Computational MD DP Model 1 30 0 0 0 0 0 0 -378.591 -197.790 -329.275 -179.156
Average of Interhelical and Total 2 15 0 0 0 0 0 0 -374.463 -168.090 -326.273 -162.401
Energy Ranks Top Structures (DP-Li/T) 3 345 0 0 0 0 0 0 -356.184 -146.130 -309.784 -140.583
4 120 15 0 0 0 0 0 -389.225 -140.950 -328.126 -114.440
5 345 0 0 0 0 0 0 -356.184 -146.130 -309.784 -140.583
6 45 0 0 0 0 0 0 -351.333 -152.880 -308.431 -157.713
7 0 15 0 0 0 0 0 -355.595 -151.770 -305.943 -136.152
8 330 0 0 0 0 0 0 -362.819 -117.460 -313.919 -126.755
9 0 0 0 0 0 0 0 -356.055 -128.000 -308.276 -126.945
10 195 0 0 0 0 0 0 -353.544 -120.970 -317.463 -130.032
GeNSEMBLE DP OptHelix Model 1 45 15 0 0 0 0 285 -350.452 -350.980 -300.705 -378.785
Average of Interhelical and Total 2 30 255 0 0 0 0 270 -347.104 -350.300 -292.886 -343.642
Energy Ranks (DP-Li/Topt) 3 45 30 0 0 0 0 135 -333.942 -357.380 -279.463 -347.817
4 45 255 0 0 0 0 285 -359.037 -340.360 -287.417 -344.603
5 30 255 0 0 0 0 15 -324.905 -353.760 -282.908 -355.431
6 60 15 0 0 0 0 285 -331.627 -340.630 -277.571 -354.245
7 45 15 0 0 0 0 15 -328.756 -367.760 -278.550 -339.249
8 45 30 0 0 0 0 15 -319.900 -348.829 -286.273 -352.862
9 90 15 0 0 0 0 15 -342.640 -336.340 -291.877 -321.726
10 15 255 0 0 0 0 15 -498.766 -492.069 -365.063 -473.321
Dopamine DRD3 DP Homology Model 1 0 345 0 0 0 0 15 -372.113 -154.740 -317.534 -204.375
Average of Interhelical and Total 2 345 345 0 0 0 0 15 -382.273 -142.330 -322.595 -178.104
Energy Ranks (DRD3/T) 3 0 0 0 0 0 0 15 -356.633 -148.580 -300.454 -182.021
4 0 15 0 0 0 0 15 -353.029 -153.750 -303.931 -175.072
5 330 345 0 0 0 0 0 -363.796 -126.869 -319.167 -161.947
6 345 15 0 0 0 0 15 -351.107 -150.680 -302.759 -173.771
7 0 0 0 0 0 0 0 -349.316 -133.630 -298.342 -181.923
8 330 0 0 0 0 0 0 -361.680 -135.410 -296.723 -157.879
9 345 345 0 0 0 0 0 -351.806 -127.680 -305.929 -154.279
10 15 0 0 0 0 0 0 -360.638 -118.580 -315.874 -153.277
η
receptor variants at the BiHelix level for 
TMD 3-4-5-6 top n
Ranking from 1-2-7  
Sampling H1 H2 H3 H4 H5 H6 H7 CInterH CTotal NInterH NTotal
Previous Computational MD DP Model 1 9 0 0 0 270 0 0 0 -398.240 -202.420 -340.355 -192.288
Average of Interhelical and Total 2 1 0 0 330 225 0 0 0 -406.645 -187.829 -340.200 -160.192
Energy Ranks Top Structures (DP-Li/T) 3 1 0 0 15 270 0 0 0 -404.526 -196.800 -335.199 -167.257
4 4 0 0 0 270 15 345 0 -410.109 -173.300 -359.667 -151.210
5 1 0 0 0 270 0 0 0 -390.878 -223.530 -338.439 -208.821
6 1 0 0 0 150 15 345 0 -397.335 -169.780 -353.585 -154.421
7 9 0 0 0 240 0 0 0 -393.383 -172.670 -339.380 -170.298
8 1 0 0 45 45 15 60 0 -404.656 -180.140 -332.938 -142.772
9 9 0 0 0 150 0 0 0 -401.990 -159.240 -341.600 -164.098
10 1 0 0 15 0 15 0 0 -395.046 -184.729 -330.702 -154.698
GeNSEMBLE DP OptHelix Model 1 8 0 0 285 270 120 345 0 -420.641 -465.918 -339.703 -428.662
Average of Interhelical and Total 2 9 0 0 270 270 120 0 0 -437.257 -433.169 -326.163 -416.776
Energy Ranks (DP-Li/Topt) 3 9 0 0 180 345 210 330 0 -456.023 -432.420 -321.046 -412.565
4 9 0 0 180 345 210 330 0 -456.023 -432.420 -321.046 -412.565
5 8 0 0 285 255 75 0 0 -414.277 -448.238 -327.523 -428.138
6 9 0 0 285 330 75 255 0 -412.076 -450.519 -321.365 -427.939
7 9 0 0 285 270 135 330 0 -443.883 -421.019 -323.284 -414.315
8 7 0 0 270 255 60 330 0 -427.844 -439.719 -309.698 -420.269
9 7 0 0 345 315 180 330 0 -421.798 -426.040 -321.010 -423.970
10 7 0 0 255 300 135 105 0 -413.377 -450.110 -316.063 -412.560
Dopamine DRD3 DP Homology Model 1 3 0 0 0 15 270 0 0 -431.463 -271.520 -376.816 -290.831
Average of Interhelical and Total 2 3 0 0 0 30 270 345 0 -433.574 -251.320 -360.984 -252.156
Energy Ranks (DRD3/T) 3 3 0 0 0 15 270 345 0 -440.350 -256.880 -367.957 -240.571
4 3 0 0 0 30 270 15 0 -429.259 -274.240 -348.703 -289.104
5 3 0 0 0 15 255 330 0 -450.742 -232.510 -377.830 -234.803
6 3 0 0 0 15 270 15 0 -426.748 -242.520 -350.853 -244.218
7 3 0 0 0 30 270 0 0 -412.330 -278.540 -355.797 -297.189
8 3 0 0 0 30 255 75 0 -421.601 -248.269 -358.352 -234.311
9 3 0 0 15 15 255 345 0 -414.671 -247.300 -352.695 -264.711
10 3 0 0 15 30 255 345 0 -418.517 -238.760 -352.549 -253.577
η
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Figure S3. A. Lowest energy binding site for CPI antagonist to the SuperCombiHelix structure from the DRD3/T 
template. Transmembrane (TM) regions 1, 2, and 7 have also been marked on the left. 
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Figure S4. DP-Li/Topt Superbihelix structure binding site (purple) superimposed on DP-Li/T Superbihelix structure 
binding site (blue). In comparing both binding sites, we note that R3107.40 is able to interact with the antagonist in the 
DP-Li/T binding site (blue) but unable to interact in the DP-Li/Topt case since it faces outside the extra-cellular pocket. 
Additionally, the presence of the L3097.39 in the DP-Li/Topt binding pocket makes it difficult for the ligand to 
comfortably bind and form interactions.  
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